IN2014MN01778A - - Google Patents
Info
- Publication number
- IN2014MN01778A IN2014MN01778A IN1778MUN2014A IN2014MN01778A IN 2014MN01778 A IN2014MN01778 A IN 2014MN01778A IN 1778MUN2014 A IN1778MUN2014 A IN 1778MUN2014A IN 2014MN01778 A IN2014MN01778 A IN 2014MN01778A
- Authority
- IN
- India
- Prior art keywords
- prodrugs
- diketone
- monosubstituted
- vitamin
- plasma
- Prior art date
Links
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005594 diketone group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 abstract 1
- 239000011700 menaquinone-7 Substances 0.000 abstract 1
- 235000019143 vitamin K2 Nutrition 0.000 abstract 1
- 239000011728 vitamin K2 Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/16—Acetic acid esters of dihydroxylic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
- C07C69/40—Succinic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/78—Benzoic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/098—Esters of polyphosphoric acids or anhydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to prodrugs of vitamin K2 in particular prodrugs of MK 7 in which the diketone is converted to a monosubstituted or disubstituted ester type derivative. These compounds are shown to give MK-7 in plasma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1203705.7A GB201203705D0 (en) | 2012-03-02 | 2012-03-02 | Prodrugs |
PCT/EP2013/054298 WO2013128037A1 (en) | 2012-03-02 | 2013-03-04 | Prodrugs of vitamine k |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN01778A true IN2014MN01778A (en) | 2015-07-03 |
Family
ID=46003017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1778MUN2014 IN2014MN01778A (en) | 2012-03-02 | 2013-03-04 |
Country Status (10)
Country | Link |
---|---|
US (2) | US9512153B2 (en) |
EP (1) | EP2819982B1 (en) |
CN (1) | CN104395273A (en) |
AU (1) | AU2013224857B2 (en) |
DK (1) | DK2819982T3 (en) |
GB (1) | GB201203705D0 (en) |
HU (1) | HUE029261T2 (en) |
IN (1) | IN2014MN01778A (en) |
PL (1) | PL2819982T3 (en) |
WO (1) | WO2013128037A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201203705D0 (en) | 2012-03-02 | 2012-04-18 | Kappa Bioscience As | Prodrugs |
GB201314245D0 (en) * | 2013-08-08 | 2013-09-25 | Kappa Bioscience As | Provitamins |
EP3139904B1 (en) | 2014-05-05 | 2021-03-03 | Basf Se | Formulation of fat-soluble vitamin |
JP6630364B2 (en) | 2015-03-27 | 2020-01-15 | ボストン バイオメディカル, インコーポレイテッド | Water-soluble prodrug |
EP3686182A4 (en) | 2017-09-22 | 2021-06-09 | Sumitomo Dainippon Pharma Co., Ltd. | Chemically activated water-soluble prodrug |
IL279245B2 (en) | 2018-06-08 | 2024-03-01 | Epizon Pharma Inc | Compositions comprising menaquinone-7 (mk-7) and/or menquinol for prophylaxis of tissue calcification |
JP2021527129A (en) | 2018-06-08 | 2021-10-11 | エピゾン・ファーマ・インコーポレイテッドEpizon Pharma, Inc. | Methods and compositions for preventing or treating calciphylaxis |
US10822295B2 (en) | 2018-09-12 | 2020-11-03 | Epizon Pharma, Inc. | Menaquinol compositions and methods of treatment |
JP7394433B2 (en) * | 2019-03-19 | 2023-12-08 | 学校法人福岡大学 | Vitamin K preparations applied under light exposure, external skin preparations, eye drops, and eye ointments using the same |
WO2022147047A1 (en) * | 2020-12-30 | 2022-07-07 | Epizon Pharma, Inc. | Compositions of biologically active menaquinol derivatives and methods of treatment |
US11912654B2 (en) | 2021-09-03 | 2024-02-27 | Synergia Life Sciences Pvt. Ltd. | Process for stereospecific synthesis of vitamin K2 and its novel intermediates |
WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
WO2023129141A1 (en) * | 2021-12-28 | 2023-07-06 | Epizon, Inc. | Compositions of biologically active menaquinol derivatives and methods of treatment |
US20230381220A1 (en) * | 2022-05-30 | 2023-11-30 | Epizon Pharma, Inc. | Pegylated menaquinol compositions and methods of treatment |
WO2023232643A1 (en) | 2022-05-31 | 2023-12-07 | Region Syddanmark | Vitamin k2 for use in treatment of coronary artery calcification |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2456686A (en) | 1944-05-11 | 1948-12-21 | President & Board Of Trustees | Process for obtaining vitamink compounds |
GB893172A (en) | 1959-10-20 | 1962-04-04 | Roche Products Ltd | A process for the manufacture of phosphoric acid esters and novel phosphoric acid esters |
US3127434A (en) * | 1959-10-20 | 1964-03-31 | Hoffmann La Roche | Dihydrovitamin k monophosphate compounds and preparation thereof |
CH575904A5 (en) | 1972-02-16 | 1976-05-31 | Eisai Co Ltd | |
GB1426769A (en) * | 1972-12-04 | 1976-03-03 | Eisai Co Ltd | Process for the production of hydroquinone derivatives |
US6746678B1 (en) | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
US8178516B2 (en) | 1992-06-30 | 2012-05-15 | Sylvan Labs, LLC | Compositions and method for treatment of chronic inflammatory diseases |
EP0679394B1 (en) | 1994-04-28 | 1998-01-14 | Eisai Co., Ltd. | Menatetronome derivative as antiarteriosclerotic agent |
JPH1035256A (en) | 1996-07-18 | 1998-02-10 | Denso Corp | Vehicular heater |
DE19964116A1 (en) | 1999-12-30 | 2001-07-05 | Liebscher Dierck H | Increasing bioavailability of magnesium ions by co-administration of vitamin K, allowing reduction of dosage in the treatment of magnesium deficiency syndrome |
JP4040082B2 (en) * | 2005-01-28 | 2008-01-30 | 学校法人福岡大学 | Cancer therapeutic agent and recurrence preventive agent using vitamin K hydroquinone derivative |
US20080220094A1 (en) | 2006-11-01 | 2008-09-11 | Wyeth | Compositions and methods for the treatment and/or prevention of osteoporosis |
EP2060256A1 (en) * | 2007-11-16 | 2009-05-20 | Gnosis S.p.A. | Pharmaceutical and nutraceutical compositions based on menaquinols |
GB0817528D0 (en) | 2008-09-24 | 2008-10-29 | Syntavit As | Process |
WO2011152810A1 (en) | 2010-06-03 | 2011-12-08 | Bilgic Mahmut | Formulations comprising calcium, vitamin d and vitamin k for osteoporosis |
WO2012161572A1 (en) | 2011-05-20 | 2012-11-29 | Friesland Brands B.V. | Composition comprising vitamin k2 |
GB201203705D0 (en) | 2012-03-02 | 2012-04-18 | Kappa Bioscience As | Prodrugs |
CN103142568B (en) | 2013-03-11 | 2015-03-11 | 昆明邦宇制药有限公司 | Calcium acetate-vitamin K pharmaceutical preparation and preparation method thereof |
-
2012
- 2012-03-02 GB GBGB1203705.7A patent/GB201203705D0/en not_active Ceased
-
2013
- 2013-03-04 PL PL13709348T patent/PL2819982T3/en unknown
- 2013-03-04 IN IN1778MUN2014 patent/IN2014MN01778A/en unknown
- 2013-03-04 US US14/382,225 patent/US9512153B2/en active Active
- 2013-03-04 AU AU2013224857A patent/AU2013224857B2/en active Active
- 2013-03-04 HU HUE13709348A patent/HUE029261T2/en unknown
- 2013-03-04 WO PCT/EP2013/054298 patent/WO2013128037A1/en active Application Filing
- 2013-03-04 CN CN201380023420.5A patent/CN104395273A/en active Pending
- 2013-03-04 DK DK13709348.0T patent/DK2819982T3/en active
- 2013-03-04 EP EP13709348.0A patent/EP2819982B1/en active Active
-
2016
- 2016-12-05 US US15/369,060 patent/US10159687B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
PL2819982T3 (en) | 2017-01-31 |
WO2013128037A1 (en) | 2013-09-06 |
CN104395273A (en) | 2015-03-04 |
DK2819982T3 (en) | 2016-11-14 |
HUE029261T2 (en) | 2017-02-28 |
GB201203705D0 (en) | 2012-04-18 |
AU2013224857A1 (en) | 2014-09-25 |
AU2013224857B2 (en) | 2016-03-17 |
US20170079994A1 (en) | 2017-03-23 |
US20150031651A1 (en) | 2015-01-29 |
EP2819982B1 (en) | 2016-09-14 |
EP2819982A1 (en) | 2015-01-07 |
US10159687B2 (en) | 2018-12-25 |
US9512153B2 (en) | 2016-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN01778A (en) | ||
EP2991935A4 (en) | Production of phosphate compounds from materials containing phosphorus and at least one of iron and aluminium | |
CR20150120A (en) | NEW BICYCLE DERIVATIVES | |
UY33735A (en) | ANTIVIRAL COMPOUNDS | |
NZ730134A (en) | Substituted tricyclic compounds as fgfr inhibitors | |
PH12015502546A1 (en) | 3-(4-isobutyl-2-methylphenyl) propanal as perfume ingredient | |
EP3397629A4 (en) | Metalloenzyme inhibitor compounds | |
MX365621B (en) | New combination. | |
MX2014010959A (en) | Phosphoric ester preparations with reduced hygroscopicity. | |
MX362752B (en) | Morphic forms of hexadecyloxypropyl-phosphonate esters. | |
IN2014DN06738A (en) | ||
PT2812332T (en) | Methods for the preparation of hiv attachment inhibitor piperazine prodrug compound | |
AU2012270029A8 (en) | Compositions and methods for modulating a kinase | |
WO2013173004A8 (en) | Radiopharmaceutical synthesis methods | |
EP3177297A4 (en) | Compositions relating to vitamin d | |
AU2013347232A8 (en) | 3-Aminocyclopentane carboxamide derivatives | |
MX2013000539A (en) | New formulations of 14 - epi -analogues of vitamin d. | |
IN2015DN00725A (en) | ||
MX350569B (en) | Stable pharmaceutical composition for treating osteoporosis. | |
EP3303599A4 (en) | Production of fragrant compounds | |
IN2014DN07410A (en) | ||
EP3609327A4 (en) | A synergistic chalcone containing composition of a nematicide | |
MX354501B (en) | Perfuming ingredient of the galbanum family. | |
IN2015DN02647A (en) | ||
SG10201704303VA (en) | Mixture for the inhibition of melanin biosynthesis |